MARKET

AGEN

AGEN

Agenus
NASDAQ
3.030
+0.150
+5.21%
After Hours: 3.060 +0.03 +1.00% 18:49 06/26 EDT
OPEN
2.880
PREV CLOSE
2.880
HIGH
3.100
LOW
2.870
VOLUME
5.01M
TURNOVER
--
52 WEEK HIGH
7.34
52 WEEK LOW
2.710
MARKET CAP
126.18M
P/E (TTM)
1.824
1D
5D
1M
3M
1Y
5Y
1D
Agenus To Present 3-Yr Survival Data From Phase 1b C-800-01 Study Of Botensilimab Plus Balstilimab In Patients With Microsatellite Stable mCRC Without Active Liver Metastases At ESMO GI 2026
Benzinga · 3d ago
Agenus announces three-year survival data from Phase 1b BOT+BAL study
TipRanks · 3d ago
Agenus to present three-year survival data from BOT+BAL Phase 1b study in MSS metastatic colorectal cancer at ESMO GI 2026
PUBT · 3d ago
AGENUS ANNOUNCES THREE-YEAR SURVIVAL DATA FROM PHASE 1B BOT+BAL STUDY IN MSS METASTATIC COLORECTAL CANCER TO BE PRESENTED AT ESMO GI 2026
Reuters · 3d ago
Agenus Shareholders Approve Governance, Compensation and Auditors
TipRanks · 5d ago
Agenus shareholders approve 5 million-share increase to 2019 equity plan at annual meeting
PUBT · 5d ago
Weekly Report: what happened at AGEN last week (0615-0619)?
Weekly Report · 6d ago
Weekly Report: what happened at AGEN last week (0608-0612)?
Weekly Report · 06/15 10:39
More
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.